BW

10
Dic
By MetroLatinoUSA
BW

New Data from bluebird bio’s Gene Therapies for Transfusion-Dependent Beta-Thalassemia and Sickle Cell Disease Presented at 64th ASH Annual Meeting

Findings from clinical studies (N=63) through eight years of long-term follow-up (n=3) continue to support ZYNTEGLO as a potentially curative one-time gene therapy for patients with beta-thalassemia who require regular red blood cell (RBC) transfusions through the achievement of durable transfusion independence and normal or near normal total hemoglobin levels…
Leer más...
10
Dic
By MetroLatinoUSA
BW

ImmunoGen Presents Findings from Expansion Cohorts in Phase 1b/2 Study of Pivekimab Sunirine with Vidaza® and Venclexta® in Acute Myeloid Leukemia at ASH

Broad Anti-Leukemia Activity in Relapsed/Refractory and Frontline AML Presented in Oral Session Recommended Phase 2 Dose Well-Tolerated; Determination of Optimal Venclexta Duration Ongoing in Separate Cohorts WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced initial…
Leer más...
10
Dic
By MetroLatinoUSA
BW

Adicet Bio Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)

ADI-001 demonstrated 75% overall response rate (ORR) and 69% complete response (CR) across all dose levels with favorable safety and tolerability profile in patients with relapsed/refractory high-grade aggressive NHL, as of December 5, 2022 data-cut date 100% ORR and CR rate in 5/5 anti-CD19 autologous chimeric antigen receptor T cells…
Leer más...
10
Dic
By MetroLatinoUSA
BW

Syros Presents Safety Lead-in Data from SELECT-AML-1 Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine and Announces Plans to Initiate Randomized Portion of Phase 2 Trial

– 83% composite complete response rate in newly diagnosed unfit AML patients with RARA gene overexpression – - Initial safety and clinical activity profile of the triplet regimen supports advancing SELECT-AML-1 into the randomized portion– – Management to host conference call at 12:00 p.m. ET today – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros…
Leer más...
10
Dic
By MetroLatinoUSA
BW

Innate Pharma Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced Sézary Syndrome at ASH 2022

Lacutamab demonstrated encouraging efficacy and a favorable safety profile in heavily pretreated, post-mogamulizumab patients with advanced Sézary syndrome In addition, Innate’s ANKETTM (Antibody-based NK cell Engager Therapeutics) platform on display at ASH via oral presentation and posters MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate”…
Leer más...
10
Dic
By MetroLatinoUSA
BW

Orum Therapeutics Presents Positive Preclinical Data of ORM-6151, a First-in-Class, CD33-GSPT1 Dual-Precision Targeted Protein Degrader for AML, at ASH 2022

BOSTON & DAEJEON, South Korea--(BUSINESS WIRE)--#ADC--Orum Therapeutics, a private biotechnology company pioneering the development of tumor-directed targeted protein degraders (TPDs), today announced the presentation of positive preclinical data for ORM-6151, a first-in-class, anti-CD33 antibody-enabled GSPT1 degrader for acute myeloid leukemia (AML), at the 64th American Society of Hematology (ASH 2022)…
Leer más...
10
Dic
By MetroLatinoUSA
BW

Precision BioSciences Presents Analysis of Azer-Cel, Allogeneic CAR T Product Attributes Related to In Vivo Pharmacokinetics, Pharmacodynamics, and Clinical Outcomes at 2022 American Society of Hematology Annual Meeting

- Cryopreserved, Post-thaw CAR T Cell Composition and Effective CAR T Cell Dose are Predictive for Response to Treatment with Azer-cel - Peak CAR T Expansion, a Key Determinant of Durable Response, Strongly Correlated with Effective CAR T Dose DURHAM, N.C.--(BUSINESS WIRE)--$DTIL #ARCUS--Precision BioSciences (Nasdaq: DTIL), a clinical stage gene…
Leer más...
10
Dic
By MetroLatinoUSA
BW

Vertex and CRISPR Therapeutics to Present at the American Society of Hematology (ASH) Annual Meeting and Exposition

- Oral presentation of encore clinical data from Phase 3 clinical trials of exa-cel - - Oral and poster presentations on quality-of-life impacts of sickle cell disease or transfusion-dependent beta-thalassemia and burden of hematopoietic stem cell transplant - BOSTON and ZUG, Switzerland--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics…
Leer más...
¡Síguenos en Facebook!
¡Síguenos en Twitter!